Compare HCAT & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | CVRX |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 139.8M |
| IPO Year | 2019 | 2021 |
| Metric | HCAT | CVRX |
|---|---|---|
| Price | $1.85 | $3.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $2.53 | ★ $10.50 |
| AVG Volume (30 Days) | 856.8K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.48 | ★ 10.45 |
| 52 Week Low | $0.96 | $2.20 |
| 52 Week High | $3.79 | $11.30 |
| Indicator | HCAT | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 36.00 |
| Support Level | $1.61 | N/A |
| Resistance Level | $2.37 | $6.06 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | -0.05 | -0.22 |
| Stochastic Oscillator | 26.35 | 24.21 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.